EMERGENT BIOSOLUTIONS INC. Interest on Convertible Debt, Net of Tax
EMERGENT BIOSOLUTIONS INC. (EBS) reported Interest on Convertible Debt, Net of Tax of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Notes
us-gaap:InterestOnConvertibleDebtNetOfTax · last filed 2020-02-25
- EMERGENT BIOSOLUTIONS INC. interest on convertible debt, net of tax for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest on convertible debt, net of tax for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest on convertible debt, net of tax for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest on convertible debt, net of tax for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest on convertible debt, net of tax for fiscal 2019 was $0.00.
- EMERGENT BIOSOLUTIONS INC. interest on convertible debt, net of tax for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. interest on convertible debt, net of tax for fiscal 2017 was $2.60M, a 21.21% decline from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. interest on convertible debt, net of tax for fiscal 2016 was $3.30M, a 9.31% increase from fiscal 2015.
| Period end | Interest on Convertible Debt, Net of Tax 3 month | Interest on Convertible Debt, Net of Tax 6 month | Interest on Convertible Debt, Net of Tax 9 month | Interest on Convertible Debt, Net of Tax 12 month | Interest on Convertible Debt, Net of Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | $0.00 10-K · filed 2020-02-25 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-02 | $0.00 derived: sum of 2 quarters · filed 2018-11-02 | $0.00 10-Q · filed 2018-11-02 | $155.00K derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-03 | $0.00 10-Q · filed 2018-08-03 | $155.00K derived: sum of 3 quarters · filed 2020-02-25 | $859.00K derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-04 | $155.00K derived: sum of 2 quarters · filed 2020-02-25 | $859.00K derived: sum of 3 quarters · filed 2020-02-25 | $1.69M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2017-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $859.00K derived: sum of 2 quarters · filed 2020-02-25 | $1.69M derived: sum of 3 quarters · filed 2020-02-25 | $2.60M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $704.00K 10-Q · filed 2018-11-02 | $1.54M derived: sum of 2 quarters · filed 2018-11-02 | $2.44M 10-Q · filed 2018-11-02 | ||
| 2017-06-30 | $835.00K 10-Q · filed 2018-08-03 | $1.74M 10-Q · filed 2018-08-03 | |||
| 2017-03-31 | $907.00K 10-Q · filed 2018-05-04 | ||||
| 2016-12-31 | $3.30M 10-K · filed 2019-02-22 | $3.25M 10-K · filed 2017-02-28 | |||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-05 | $0.00 10-Q · filed 2016-08-05 | $1.36M derived: sum of 3 quarters · filed 2017-02-28 | $2.14M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2016-03-31 | $716.00K 10-Q · filed 2016-05-06 | $1.36M derived: sum of 2 quarters · filed 2017-02-28 | $2.14M derived: sum of 3 quarters · filed 2017-02-28 | $2.95M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-12-31 | $641.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $1.43M derived: sum of 2 quarters · filed 2017-02-28 | $2.24M derived: sum of 3 quarters · filed 2017-02-28 | $3.02M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $786.00K 10-Q · filed 2015-11-06 | $1.59M derived: sum of 2 quarters · filed 2016-08-05 | $2.38M 10-Q · filed 2015-11-06 | $4.47M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | $809.00K 10-Q · filed 2016-08-05 | $0.00 10-Q · filed 2016-08-05 | $3.69M derived: sum of 3 quarters · filed 2017-02-28 | $4.61M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-06 | $2.88M derived: sum of 2 quarters · filed 2017-02-28 | $3.80M derived: sum of 3 quarters · filed 2017-02-28 | $3.80M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2014-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $3.80M derived: sum of 2 quarters · filed 2017-02-28 | $3.80M derived: sum of 3 quarters · filed 2017-02-28 | $2.88M 10-K · filed 2017-02-28 | |
| 2014-09-30 | $917.00K 10-Q · filed 2015-11-06 | $917.00K derived: sum of 2 quarters · filed 2015-11-06 | $0.00 10-Q · filed 2015-11-06 | $917.00K derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-06 | $0.00 10-Q · filed 2015-08-06 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-08 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 derived: sum of 4 quarters · filed 2016-02-29 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 | |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-10 | $0.00 derived: sum of 2 quarters · filed 2014-11-10 | $0.00 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-08 | $0.00 10-Q · filed 2014-08-08 | |||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-12 | ||||
| 2012-12-31 | $0.00 10-K · filed 2015-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |